Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INTRAVENOUS AMIODARONE FOR RECURRENT SUSTAINED HYPOTENSIVE VENTRICULAR TACHYARRHYTHMIAS
Autore:
LEVINE JH; MASSUMI A; SCHEINMAN MM; WINKLE RA; PLATIA EV; CHILSON DA; GOMES A; WOOSLEY RL;
Indirizzi:
ST FRANCIS HOSP,ARRHYTHMIA SERV,CTR HEART,100 PORT WASHINGTON BLVD ROSLYN NY 11576 ST LUKES EPISCOPAL HOSP,TEXAS MED CTR HOUSTON TX 77030 UNIV CALIF SAN FRANCISCO,MED CTR SAN FRANCISCO CA 94143 SEQUOIA HOSP REDWOOD CITY CA 00000 WASHINGTON HOSP WASHINGTON DC 00000 DEACONESS HOSP SPOKANE WA 00000 MT SINAI MED CTR NEW YORK NY 10029 GEORGETOWN UNIV WASHINGTON DC 00000
Titolo Testata:
Journal of the American College of Cardiology
fascicolo: 1, volume: 27, anno: 1996,
pagine: 67 - 75
SICI:
0735-1097(1996)27:1<67:IAFRSH>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
CLINICAL EFFICACY; ARRHYTHMIAS; THERAPY; TACHYCARDIA; AGENT;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
11
Recensione:
Indirizzi per estratti:
Citazione:
J.H. Levine et al., "INTRAVENOUS AMIODARONE FOR RECURRENT SUSTAINED HYPOTENSIVE VENTRICULAR TACHYARRHYTHMIAS", Journal of the American College of Cardiology, 27(1), 1996, pp. 67-75

Abstract

Objectives. We sought to determine the response rate and safety of intravenous amiodarone in patients with ventricular tachyarrhythmias refractory to standard therapies. Background. Numerous small retrospective reports suggest a response of refractory ventricular tachyarrhythmias to intravenous amiodarone, get no controlled prospective trials exist. Methods. Two hundred seventy-three patients with recurrent hypotensive ventricular tachyarrhythmias refractory to lidocaine, procainamideand bretylium were randomized to receive one of three doses of intravenous amiodarone: 525, 1,050 or 2,100 mg/24 h (mean [+/- SE] dose 743.7 +/- 418.7, 1,175.2 +/- 483.7, 1,921.2 +/- 688.8 mg, respectively) bycontinuous infusion over 24 h. Results. Of the 273 patients, 110 (40.3% response rate) survived 24 h without another hypotensive ventricular tachyarrhythmic event while being treated with intravenous amiodarone as a single agent (primary end point). A significant difference in the time to first recurrence of ventricular tachyarrhythmia (post hoc analysis) over the first 12 h was observed when the combined 1,050- and2,100-mg dose groups were compared with the 525-mg dose group (p = 0.046). The number of supplemental (150 mg) infusions of intravenous amiodarone (given for breakthrough destabilizing tachyarrhythmias) duringhours 0 to 6 (prespecified secondary end point) was significantly greater in the 525-mg dose group than in the 2,100-mg dose group (1.09 +/- 1.57 vs. 0.51 +/- 0.97, p = 0.0043). However, there was no clear dose response relation observed in this trial with respect to success rates (primary end point), time to first recurrence of tachyarrhythmia (post hoc analysis) or mortality (secondary end point) over 24 h, Conclusions. Intravenous amiodarone is a relatively safe therapy for ventricular tachyarrhythmias refractory to other medications.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 01:21:54